Back to top
more

Aphria Inc. (APHA)

(Delayed Data from NYSE)

$6.94 USD

6.94
5,631,062

-0.19 (-2.66%)

Updated May 3, 2019 04:02 PM ET

After-Market: $7.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about LabCorp (LH) on increasing demand for COVID-19 tests as well as robust first-quarter 2020 results.

PRA Health Boosts Health Harmony COVID-19 Monitoring Program

by Zacks Equity Research

PRA Health (PRAH) gives a boost to COVID-19 Monitoring program through collaboration with the Microsoft Healthcare Bot service.

Medtronic's CE Marked MiniMed 780G to Aid Diabetes Management

by Zacks Equity Research

Medtronic's (MDT) CE Marked advanced hybrid closed loop system, MiniMed 780G, is aimed at enhancing management of type 1 diabetes.

Intersect ENT's Sinuva Adoption to Rise on New C-Code by CMS

by Zacks Equity Research

This latest reimbursement development broadens Intersect ENT's (XENT) already-extensive customer base to a significant extent.

Here's Why You Should Retain VEEVA Systems (VEEV) Stock Now

by Zacks Equity Research

Investor confidence is high in VEEVA Systems (VEEV), thanks to solid prospects.

    Illumina's (ILMN) NGS Test for Detecting Coronavirus Gets EUA

    by Zacks Equity Research

    Illumina's (ILMN) NGS-based test for the detection of the SARS-CoV-2 receives the FDA's EUA to enable high-volume screening.

    Surmodics Gets CE Mark for SurVeil Drug-Coated Balloon

    by Zacks Equity Research

    Surmodics' (SRDX) receipt of CE Mark for SurVeil DCB should boost the company's Medical Devices segment.

      DexCom's (DXCM) G6 CGM System Gets CE Marking in Europe

      by Zacks Equity Research

      DexCom (DXCM) announces the receipt of CE Marking across Europe for its G6 CGM System.

      Myriad Genetics' Test Better Predicts Drug Levels Per Study

      by Zacks Equity Research

      Myriad Genetics' (MYGN) GeneSight Psychotropic test is shown to be superior at predicting blood concentrations unlike single-gene testing as demonstrated by a latest study.

      Medtronic's StealthStation Feature Recall Classified Class I

      by Zacks Equity Research

      This is not the first time, Medtronic's (MDT) StealthStation surgical navigation system is facing product recall.

      Globus Medical Faces Business Loss Amid Coronavirus Crisis

      by Zacks Equity Research

      Globus Medical (GMED) notes that the U.S. spine business bottomed in the first full week of April, witnessing a decline of about 70% from its pre-COVID 19 pace.

      Edwards Lifesciences' SAPIEN 3 THV Cleared for Use in China

      by Zacks Equity Research

      Edwards Lifesciences' (EW) SAPIEN 3 THV to be used an alternative to open-heart surgery for high and extreme-risk AS patients post approval in China.

      Here's Why You Should Retain LHC Group (LHCG) Stock Now

      by Zacks Equity Research

      Investor confidence is high in LHC Group (LHCG), thanks to solid prospects

      Here's Why You Should Hold on to Stryker (SYK) Stock for Now

      by Zacks Equity Research

      Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako, broad product portfolio and solid international growth. However, pricing pressure raises concern.

      Hexo Corp. (HEXO) to Post Q3 Earnings: What's in the Offing?

      by Zacks Equity Research

      Hexo's (HEXO) fiscal third-quarter results are likely to reflect operational efficiency and strong product portfolio.

      Medtronic Resolute Onyx Gets CE Mark for 1-Month DAPT Therapy

      by Zacks Equity Research

      Medtronic's (MDT) gets CE Mark recognition for a shorter DAPT indication for HBR patients with Resolute Onyx DES implantation who are at higher risk of bleeding.

      IDEXX OPTI Medical Gets CE Mark for RT-PCR Coronavirus Test

      by Zacks Equity Research

      This test by IDEXX (IDXX) benefits from an optimized workflow and claims to deliver greater assurance of quality and accuracy.

      Bio-Rad Rides on New Coronavirus Tests Amid Cost Concerns

      by Zacks Equity Research

      The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues results from robust demand for coronavirus testing and related research.

      Here's Why You Should Hold on to Haemonetics Stock for Now

      by Zacks Equity Research

      Investors continue to be optimistic about Haemonetics (HAE) on sustained underlying product demand and geographical expansion.

      ABIOMED Gets FDA Nod for First-in-Human Trial of Impella ECP

      by Zacks Equity Research

      This regulatory approval is expected to boost ABIOMED's (ABMD) Impella product line.

      Here's Why You Should Retain NextGen Healthcare Stock Now

      by Zacks Equity Research

      NextGen Healthcare (NXGN) continues to benefit from growing RCM and EHR markets, and solid recurring revenue base.

      Ecolab's AdvaCare Disinfectant Receives First EPA Approval

      by Zacks Equity Research

      Ecolab's (ECL) AdvaCare Disinfectant receives first EPA approval for a laundry disinfectant and oxidizer emerging viral pathogen claim that is effective against the coronavirus.

      Cooper Companies (COO) Misses on Q2 Earnings and Revenues

      by Zacks Equity Research

      Cooper Companies' (COO) fiscal second-quarter earnings reflect dismal segmental performance and decline in revenues.

      Here's Why You Should Retain AmerisourceBergen Stock Now

      by Zacks Equity Research

      Investor confidence is high on AmerisourceBergen (ABC) stock, thanks to solid prospects.

      Haemonetics (HAE) Inks Deal With GVS for Blood Filter Supply

      by Zacks Equity Research

      Haemonetics (HAE) inks deal to enhance operations and provide high quality products through an asset-lite approach in its blood filters operations.